Bergk Verena, Haefeli Walter E, Gasse Christiane, Brenner Hermann, Martin-Facklam Meret
Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Eur J Clin Pharmacol. 2005 Jul;61(5-6):327-35. doi: 10.1007/s00228-005-0943-4. Epub 2005 Jun 28.
To compare comprehensiveness and accuracy of drug interaction information in the German summary of product characteristics (SPC) with current evidence from the literature and to evaluate the SPC's usefulness with respect to management of drug interactions.
Information on clinically relevant drug interactions was compared between the SPC and three standard information sources on drug interactions (DRUGDEX, Hansten/Horn's Drug Interactions Analysis and Management, Stockley's Drug Interactions) according to five consecutive criteria (inclusion, appropriateness of class labelling, effect description, management recommendation, explicit dose adjustment). Using medication data of an outpatient population (n=4,949), we determined what percentage of insufficiently characterized combinations indeed occurred in outpatients treated with combination drug therapy.
Only for 33% (192/579) of the evaluated combinations did SPCs provide drug interaction information equivalent to the evidence from the published literature. Of the clinically relevant drug interactions, 16% were completely missing and 51% were insufficiently characterized compared with standard sources. Explicit management recommendations were either missing or differed from standard sources in 18% of the evaluated pairs of compounds. Of these missing or insufficiently characterized combinations, 12% (47/387) were indeed prescribed to outpatients. Those drug combinations for which the interaction potential was not mentioned in the SPC were received by 0.6% (32/4,949) of patients, and 4% (192/4,949) of patients received combinations that had insufficiently characterized drug interactions.
If physicians only rely on SPC information for drug interactions, adverse events due to lacking management recommendations may occur. To meet the SPCs claim of being the basis of information for health professionals on how to use medicinal products safely and effectively, information on drug interactions should be thoroughly up-dated and expanded.
比较德国产品特性摘要(SPC)中药物相互作用信息的全面性和准确性与当前文献证据,并评估SPC在药物相互作用管理方面的实用性。
根据五个连续标准(纳入情况、类别标签的适当性、效应描述、管理建议、明确的剂量调整),比较SPC与三个关于药物相互作用的标准信息来源(DRUGDEX、Hansten/Horn的药物相互作用分析与管理、Stockley的药物相互作用)中临床相关药物相互作用的信息。利用门诊患者群体(n = 4949)的用药数据,我们确定在接受联合药物治疗的门诊患者中,特征描述不充分的组合实际出现的百分比。
在评估的组合中,只有33%(192/579)的SPC提供的药物相互作用信息与已发表文献的证据相当。与标准来源相比,临床相关药物相互作用中有16%完全缺失,51%特征描述不充分。在评估的化合物对中,18%的明确管理建议缺失或与标准来源不同。在这些缺失或特征描述不充分的组合中,有12%(47/387)确实被开给了门诊患者。SPC中未提及相互作用潜力的那些药物组合,有0.6%(32/4949)的患者使用,4%(192/4949)的患者使用了药物相互作用特征描述不充分的组合。
如果医生仅依赖SPC中的药物相互作用信息,可能会因缺乏管理建议而发生不良事件。为了满足SPC作为健康专业人员安全有效使用药品信息基础的宣称,药物相互作用信息应彻底更新和扩充。